Vendor Review Inside Pain Management and Physical Medicine Groups
Multi-provider pain management and physical medicine practices typically assign a practice manager or compliance lead to vet a new biologics supplier before any product is approved for use. That review usually asks for the supplier's HCT/P registration status, a description of donor screening and lot release testing, and sample certificates of analysis.
Where a group spans several locations, one central vendor file is often used to cover every site, which means the initial documentation request tends to be more detailed than for a single-location clinic.
Lancaster
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
72- Pain Medicine
- 40
- Physical Medicine & Rehabilitation
- 32
Confirming Account Eligibility
Accounts with Precision Biologics open only after an NPI number tied to the ordering practice is confirmed. This restricts ordering access to licensed physicians and clinics and keeps pricing, which is available to verified accounts only, out of public view.
A practice with several affiliated providers can register under one account tied to the group's NPI, simplifying reordering across sites.
Shipping and Storage for Northeast Deliveries
Cryopreserved products ship overnight on dry ice in validated containers and require storage at -80 degrees C once received; a practice should confirm freezer space and staff availability before scheduling a first delivery. Lyophilized exosome and Wharton's jelly formats are shelf-stable and do not require cryogenic storage, which can simplify receiving for smaller practices.
Each lot carries a unique identifier for tracking at the patient-record level once product reaches the clinic.
Documentation, Medical Director Sign-Off, and Counsel
Certificates of analysis, donor eligibility summaries, and lot release records are available to verified accounts on request. Precision Biologics does not determine whether a specific intended use meets the homologous-use and minimal-manipulation criteria in 21 CFR 1271.10 for a Wharton's jelly product, or how an exosome product should be classified for a given use; those are determinations for the practice's medical director and legal counsel, and clinics should also verify requirements with the Pennsylvania State Board of Medicine.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management group with locations outside Lancaster still order under one account?+
Yes. An account is tied to the group's NPI rather than a single address, so affiliated providers across locations can order under one verified account.
Are exosome products handled differently from Wharton's jelly products for documentation purposes?+
Yes. FDA has stated there are no FDA-approved exosome products and generally regulates them as biologic drugs, so documentation and classification questions for exosome products should go through the practice's own regulatory counsel separately from Wharton's jelly product questions.
What is the first step for a Lancaster-area practice to start the account process?+
Submit an NPI number and practice name for verification. Once confirmed, the account can request documentation and begin ordering.